N-Isopropyl-1-[3-(3-hydroxy-3-phenylbut-1-ynyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide | 500355-51-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: N-Isopropyl-1-[3-(3-hydroxy-3-phenylbut-1-ynyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide
• 英文别名: N-Isopropyl-1-[3-(3-hydroxy-3-phenylbut-1-ynyl)phenyl]-1,4-dihydro [1,8]naphthyridin-4-one-3-carboxamide；1-[3-(3-hydroxy-3-phenylbut-1-ynyl)phenyl]-4-oxo-N-propan-2-yl-1,8-naphthyridine-3-carboxamide
• CAS: 500355-51-1
• 化学式: C₂₈H₂₅N₃O₃
• 分子量: 451.525
• InChiKey: OJHOCHSVVQTTFZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  82.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-(3-Bromophenyl)-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxylic Acid 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride copper(l) iodide 、 三乙胺 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 N-Isopropyl-1-[3-(3-hydroxy-3-phenylbut-1-ynyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide
  参考文献：
  名称：

  Alternative Forms of the Phosphodiesterase-4 Inhibitor N-Cyclopropyl-1--4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide

  摘要：

  本发明涉及选择性磷酸二酯酶4抑制剂的替代形式，其结构式如下所示：

  公开号：

  US20110245290A1

文献信息

• Alkyne-aryl phosphodiesterase-4 inhibitors
  申请人：——

  公开号：US20030114478A1

  公开（公告）日：2003-06-19

  Compounds represented by Formula (I): 1 or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation.

  由公式(I)表示的化合物： 1 或其药用可接受的盐，是磷酸二酯酶4抑制剂，用于治疗哮喘和炎症。
• [EN] ALTERNATIVE FORMS OF THE PHOSPHODIESTERASE-4 INHIBITOR N-CYCLOPROPYL-1-{3-[(1-OXIDOPRYIDIN-3-YL)ETHYNYL]PHENYL}-4-OXO-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXYAMIDE<br/>[FR] FORMES ALTERNATIVES DU N-CYCLOPROPYL-1-{3-[(1-OXIDOPRYIDIN-3-YL)ETHYNYL]PHENYL}-4-OXO-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXYAMIDE, UN INHIBITEUR DE PHOSPHODIESTERASE DE TYPE 4
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2005105084A1

  公开（公告）日：2005-11-10

  The present invention is directed to alternative forms of the title phosphodiesterase 4 inhibitor which has the structural formula shown immediately below: Compound IX

  本发明涉及磷酸二酯酶4抑制剂的替代形式，其结构式如下所示：化合物IX。
• Use of phosphodiesterase-4 inhibitors as enhancers of cognition
  申请人：Dube Daniel

  公开号：US20060040981A1

  公开（公告）日：2006-02-23

  The present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of a phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and effective amount of a phosphodiesterase-4 inhibitor.

  本发明涉及一种增强健康受试者认知能力的方法，包括给予安全的磷酸二酯酶-4抑制剂增强认知能力的剂量。特别地，本发明涉及一种增强健康受试者记忆、学习、保留、回忆、意识和判断力的方法，包括给予安全有效的磷酸二酯酶-4抑制剂的剂量。
• Use of pde4 inhibitors as adjunct therapy for psychiatric disorders
  申请人：Scolnick M. Edward

  公开号：US20060069115A1

  公开（公告）日：2006-03-30

  The use of a PDE4 inhibitor in conjunction with psychotherapy provides enhanced therapeutic results in the treatment of psychiatric disorders including, for example, specific phobias, panic disorders, anxiety disorders including posttraumatic stress disorders, and obsessive-compulsive disorder.

  在治疗精神障碍，例如特定恐惧症、惊恐障碍、包括创伤后应激障碍和强迫症的焦虑障碍中，与心理治疗同时使用PDE4抑制剂可以提供增强的治疗效果。
• Altenrative Forms Of The Phosphodeisterase -4 Inhibitor N-Cyclopropyl-1- -3{3-[(1-Oxidopyryidin-3-Yl) Phenyl]-4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide
  申请人：Clas Sophie-Dorothee

  公开号：US20080119509A1

  公开（公告）日：2008-05-22

  The present invention is directed to alternative forms of the title phosphodiesterase 4 inhibitor which has the structural formula shown immediately below: Compound IX

  本发明涉及一种替代的磷酸二酯酶4抑制剂，其结构式如下所示：化合物IX。